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Pulmonary carcinoids comprise a well-differentiated subset of 
neuroendocrine tumors usually associated with a favorable prog-
nosis, but mechanisms underlying disease progression are poorly 
understood. In an explorative approach to identify pathways asso-
ciated with progression, we compared gene expression profiles of 
tumors from five patients with a favorable and five with a poor dis-
ease outcome. Differentially expressed genes were validated using 
quantitative real-time PCR on 65 carcinoid tumors, in combination 
with survival analysis. One of the identified pathways was further 
examined using immunohistochemistry. As compared with other 
chromosomal locations, a significantly higher number of genes 
downregulated in carcinoids with a poor prognosis were located 
at chromosome 11q (P = 0.00017), a region known to be frequently 
lost in carcinoids. In addition, a number of upregulated genes were 
found involved in the mitotic spindle checkpoint, the chromosomal 
passenger complex (CPC), mitotic kinase CDC2 activity and the 
BRCA-Fanconi anemia pathway. At the individual gene level, 
BIRC5 (survivin), BUB1, CD44, IL20RA, KLK12 and OTP were 
independent predictors of patient outcome. For survivin, the num-
ber of positive nuclei was also related to poor prognosis within the 
group of carcinoids. Aurora B kinase and survivin, major compo-
nents of the CPC, were particularly upregulated in high-grade car-
cinomas and may therefore comprise therapeutic targets for these 
tumors.  To our knowledge, this is the first expression profiling study 
focusing specifically on pulmonary carcinoids and progression. We 
have identified novel pathways underlying malignant progression 
and validated several genes as being strong prognostic indicators, 
some of which could serve as putative therapeutic targets.
Introduction
Pulmonary carcinoids are well-differentiated neuroendocrine tumors 
with little relation to cigarette smoking (1). In contrast to other lung 
neuroendocrine neoplasms (NENs), i.e. the poorly differentiated large 
cell neuroendocrine carcinoma and small cell lung cancer (SCLC), 
carcinoids are characterized by a low metastatic rate and a relatively 
favorable prognosis. According to the World Health Organization, 
based on histopathologic features, lung carcinoids are subclassified as 
typical carcinoid or atypical carcinoid (AC) (2), and the latter being 
characterized by a more aggressive clinical behavior and a lower 5 
year survival (3). Pulmonary carcinoids are considered as separate 
entities and transitions from typical to atypical subtypes have not 
been reported (1). Metastases will usually develop in regional lymph 
nodes, but also at distant sites including liver, bone, brain, subcutane-
ous tissue and breast (1,3). Clinical management of metastatic disease 
remains difficult and a curative treatment strategy for these cases is 
not available (1,4). Metastatic lung carcinoids are usually subjected 
to SCLC treatment regimens, but their response rate is considerably 
lower (4).
Pulmonary carcinoids have been reported in the context of the mul-
tiple endocrine neoplasia type 1 syndrome and a number of sporadic 
tumors have a mutation of the MEN1 gene (5,6). We have previously 
described a tentative model for the tumorigenesis of pulmonary carci-
noids (1). However, although clinical and molecular parameters with 
prognostic value have been described previously (1,7–10), the pro-
cesses underlying malignant progression of lung carcinoids, defined 
as extensive spread of the disease and/or distant metastasis, are poorly 
understood (1). We have previously found that deletion of chromo-
some 11q22.3–q25 is associated with ACs and a poor disease outcome 
(9). Furthermore, aggressive carcinoids may show a high Bcl-2/Bax 
ratio, indicating that apoptosis may be hampered (11). Ki-67 may or 
may not be enhanced in cases with a poor disease outcome (12,13), 
whereas CD44 may be lost in aggressive cases (10,14). To identify 
molecular parameters that distinguish tumors with a favorable out-
come from those with a poor clinical outcome, genome-wide gene 
expression profiling has proven helpful (15). However, only few of 
such studies that included lung carcinoids have been published (16–
20), whereas none of these studies focused specifically on carcinoid 
tumors and progression (1).
In the underlying study, differentially expressed genes and asso-
ciated pathways involved in carcinoid progression were identified 
using high-resolution gene expression microarrays on carcinoids 
from patients with a very poor disease outcome on the one hand and 
those of patients with a favorable outcome on the other. These path-
ways, as well as the prognostic value of a number of candidate genes, 
were validated by quantitative real-time PCR (qRT–PCR) as well as 
immunohistochemistry. The findings were also related to the results 
from high-resolution array comparative genomic hybridization (array 
CGH) assays.
Materials and methods
For more information, see Supplementary Materials and methods, available at 
Carcinogenesis Online.
Tumor material and case selection
In order to discover novel genes associated with pulmonary carcinoid pro-
gression, 10 pulmonary carcinoids were subjected to microarray experiments. 
Frozen tissue (≥70% tumor cells) was selected from five tumors of carcinoid 
patients with a favorable prognosis (all ≥7 year disease-free survival without 
metastasis or recurrence) and five from patients with a very poor disease out-
come (all distant metastasis or deceased ≤3 years after diagnosis) (Table I).
Frozen tissue material (≥70% tumor cells) from 55 additional carcinoids 
and 16 high-grade neuroendocrine carcinomas was collected for qRT–PCR as 
described previously (10). In addition, nine neuroendocrine cell lines and four 
normal tissues (adrenal gland, liver, lung and pancreas) were analyzed (10). 
Formalin-fixed paraffin-embedded material of 65 pulmonary NENs (50 carci-
noids and 15 high-grade carcinomas) was included for immunohistochemistry. 
Abbreviations: ABk, Aurora B kinase; AC, atypical carcinoid; CGH, com-
parative genomic hybridization; CIN, chromosomal instability; CPC, chro-
mosomal passenger complex; FA, Fanconi anemia; mRNA, messenger RNA; 
MSC, mitotic spindle checkpoint; NEN, neuroendocrine neoplasm; NSCLC, 
non-small cell lung cancer; qRT–PCR, quantitative real-time PCR; SCLC, 
small cell lung cancer.
†These authors contributed equally to this work.
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Gene expression profiling of pulmonary carcinoids
These latter cases comprise a subset of the tumors described in detail in a 
previous study (10). The current study meets the criteria of the code for proper 
secondary use of human tissue in The Netherlands (Federation of Medical 
Scientific Societies, The Netherlands; 2003).
Sample preparation and messenger RNA expression profiling
RNA was isolated from the tumor tissues using the RNeasy Mini Kit (Qiagen 
GmbH, Hilden, Germany). RNA integrity was tested by chip analysis using the 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and was >7 for all 
samples. The RNA samples were converted to complementary DNA, subse-
quently labeled during complementary RNA conversion and hybridized onto 
Agilent Human* GE 4x44K v2 Microarrays (Agilent Technologies), according 
to the manufacturer instructions (Two-Color Microarray-Based Gene Expression 
Analysis–Low Input Quick Amp Labeling protocol, version 6.5) and not including 
the RNA Spike-In kit step (Step 1). Hybridization of each sample was performed 
in duplicate, with dye swap, once using cyanine-3 and once using cyanine-5 
fluorescent as a dye for the tumor samples. Universal Human Reference RNA 
(Stratagene, Agilent Technologies, Santa Clara, CA) from a cell line pool express-
ing 70–80% of all human genes, was hybridized onto each microarray slide as 
a control. The raw microarray data are available in the ArrayExpress database 
(http://www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-3790.
Gene selection procedures
Data processing and analysis were performed using R (21). Loess normalization 
and minimal background subtraction were carried out to correct for imbalance 
between the fluorescent dyes. After initial processing, the signals of four replicates 
(i.e. samples 2 and 3 labeled with cyanine-5 and samples 4 and 5 labeled with 
cyanine-3) showed a generally deviant behavior, and were therefore excluded from 
further analysis. The expression profile was determined for each sample by calcu-
lating the natural logarithm of the average across all replicates. For the four sam-
ples without available replicate, the expression profile was based on a single array.
Because of the low number of samples included in the expression array 
analyses, a stringent selection was performed to determine differentially 
expressed genes between the two groups (see Supplementary Table S1, avail-
able at Carcinogenesis Online). Subsequently, the log2 ratio of all these dif-
ferential expression ratios was calculated and differentially expressed genes in 
the poor prognosis group were identified using a cutoff of 0.5 on the log2 scale. 
This resulted in 307 unique genes (as identified from 681 probes, i.e. 1.5%, 
on the microarray) that were differentially expressed between the carcinoids 
with a poor and a favorable disease outcome (arranged according to median 
fold change in Supplementary Table S1, available at Carcinogenesis Online). 
A selection of 71 top candidate genes is shown in Table II.
Pathway analysis
The 307 altered genes between the two prognostic groups (Supplementary 
Table S1, available at Carcinogenesis Online) were subjected to pathway 
analysis using DAVID (http://david.abcc.ncifcrf.gov/; DAVID Bioinformatics 
Resources 6.7, NIAID, NIH, Bethesda, MD). Furthermore, the literature was 
thoroughly screened in search of additional relationships between top candi-
date genes. Interactions between candidate genes were also identified using the 
online BioGRID tool (http://thebiogrid.org; version 3.1).
Quantitative RT–PCR
Results of the gene expression microarrays were validated using qRT–PCR 
on 65 carcinoids (including the 10 cases subjected to gene expression profil-
ing) and 16 high-grade lung NENs. RNA processing and qRT–PCR were per-
formed as described previously (10), using the primers listed in Supplementary 
Table S2, available at Carcinogenesis Online. These were designed to detect 
the housekeeping genes ACTB, CYPA, GUSB and HPRT, and the differentially 
expressed BIRC5, BUB1, FANCA, FOLR1, IL20RA, KLK12, MT1F and PCK1 
genes. The qRT–PCR procedure is further described in the Supplementary 
Data, available at Carcinogenesis Online.
Immunohistochemistry
One of the identified pathways, i.e. the chromosomal passenger complex (CPC), 
was further examined using immunohistochemistry for Aurora B kinase (ABk) 
and survivin (the BIRC5 gene product) on formalin-fixed paraffin-embedded 
and frozen material of 50 carcinoids and 15 high-grade neuroendocrine carci-
nomas. The following antibodies were used: (i) mouse anti-ABk monoclonal 
antibody, clone 6/AIM-1 (BD Transduction Laboratories, Lexington, KY); 
(ii) rabbit anti-survivin polyclonal antibody (AF886; R&D systems, Boston, 
MA). Mouse anti-Ki-67 monoclonal antibody, clone MIB-1 (Dako, Glostrup, 
Denmark) was used to determine proliferation in the 10 cases subjected to gene 
expression profiling. The assay conditions are described in the Supplementary 
Data, available at Carcinogenesis Online.
The immunohistochemical staining patterns were evaluated as follows. 
Frequencies of ABk- and survivin-positive nuclei were calculated after 
manually counting ≥500 nuclei. Cytoplasmic positivity was scored when dif-
fusely present with a considerable intensity. Frequencies of Ki-67-positive 
cells were calculated using an automated cell-counting approach.
Array CGH
To identify chromosomal alterations in the 10 cases subjected to gene expres-
sion profiling (Table IA), DNA isolated from these cases was hybridized onto 
NimbleGen Human CGH 3x720K Whole-Genome Tiling v3.0 Arrays (Roche 
NimbleGen, Madison, WI), as described in the Supplementary Data, avail-
able at Carcinogenesis Online. The raw array CGH data are available in the 
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession 
number E-MEXP-3806.
Correlation of molecular parameters with clinical follow-up
Possible correlations between clinical data and qRT–PCR results were deter-
mined using IBM SPSS Statistics (version 20.0.0; IBM, New York, NY). 
Survival curves were created using the Kaplan–Meier method. Cutoff points 
for gene expression levels and frequencies of nuclear immunoreactivity were 
determined using area under the receiver operating characteristic curve analy-
sis. The log-rank test was used to test for differences between subgroups. 
Overall survival was calculated from the date of diagnosis until patient’s 
death or until the last date the patient was known to be alive. Multivariate 
analyses were performed using Cox regression, including age at diagnosis, 
diameter, histopathology, sex and qRT–PCR results for the individual genes. 
Differences in gene and protein expression levels for different tumor sub-
groups were determined using the Student’s t-test. The chi-square test was 
used to calculate the overrepresentation of downregulated genes on chromo-
some 11q. All P values were considered statistically significant if ≤0.05 for 
two-sided tests.
Results
In order to discover novel genes associated with pulmonary carcinoid 
progression, frozen material from five pulmonary carcinoids with a 
favorable prognosis and five with an adverse prognosis was retrieved 
from our archives. Clinical data and tumor characteristics of these 
cases are shown in Table IA. All cases were consensus classified as pul-
monary carcinoids by at least two pathologists according to the World 
Health Organization classification (2). Our subjects (four males, six 
females, mean age 54  years, range 22–69) were selected based on 
their disease outcome, thus irrespective of histopathologic classifica-
tion into ACs and typical carcinoids, which is difficult leading to a 
high interobserver variation (22). In accordance with the literature 
(9,23), the ploidy status of these cases was found to be diploid based 
on FISH, whereas the MIB-1 proliferative capacity of the tumors 
ranged between 0 and 33% (Table IB and Supplementary Figure S1, 
available at Carcinogenesis Online). Because of the high proliferative 
index of cases 1 and 4, we decided to further examine the cases with a 
poor prognosis for TP53 mutation, an infrequent event in pulmonary 
carcinoids (1). Case 1 exhibited mutation Y236C in exon 7, although 
the TP53-mutated allele was present 3–4 times less frequently than 
the wild-type allele. Immunohistochemistry confirmed the heteroge-
neity of this case since only part of the tumor cells were p53 positive 
(data not shown).
Identification of genes differentially expressed between pulmonary 
carcinoids with a favorable and a poor prognosis
Using expression profiling, 307 genes (Supplementary Table S1, 
available at Carcinogenesis Online) were found to be differentially 
expressed to a significant degree in the five lung carcinoids with 
a favorable prognosis as compared with the five with a poor out-
come. A  selection of 71 annotated candidates with a median fold 
change ≥5 from these 307 is shown in Table II. The gene showing 
the strongest upregulation in cases with a poor prognosis was the 
RET proto-oncogene (10). Among the 23 genes upregulated with a 
median fold change ≥5 were also factors involved in cell cycle con-
trol mechanisms, including ASPM, BIRC5 (survivin), BUB1, CASC5 
(blinkin), CEP55, FANCA, HIST1H3B, ORC6L, RCC1 and UBE2C, 
the angiogenic growth factor SMOC2 and the secreted serine pro-
tease KLK12. The strongest downregulation in cases with a poor 
prognosis was seen for the orthopedia homeobox gene OTP (10). 
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Table II. Differentially expressed genes between lung carcinoids with a poor and a favorable prognosisa
Gene abbreviationb Median (poor prognosis) Median (good prognosis) Median fold change Chromosomal locationc Gene name
Upregulated genes in carcinoids with a poor prognosis
 RET 1187.91 19.80 59.987 10q11.2 RET proto-oncogene
 KLK12 233.55 10.01 23.325 19q13.33 Kalikrein 12
 SMOC2 7075.18 432.61 16.355 6q27 SPARC-related modular calcium 
binding 2
 HBB 8394.37 632.69 13.268 11p15.5 Beta-hemoglobin
 POTEB 231.15 19.80 11.672 15q11.2 POTE ankyrin domain family, 
member B
 BUB1 144.99 12.65 11.457 2q14 Budding uninhibited by benzimida-
zoles 1 homolog (yeast)
 ORC6L 152.08 15.59 9.753 16q12 Origin recognition complex, 
subunit 6
 METRNL 3167.14 341.29 9.280 17q25.3 METRNL meteorin, glial cell dif-
ferentiation regulator-like
 PTTG2 809.69 89.45 9.052 4p12 Pituitary tumor-transforming 2
 FANCA 53.75 5.98 8.996 16q24.3 Fanconi anemia, complementation 
group A
 KAZALD1 914.66 109.56 8.348 10q24.31 Kazal-type serine peptidase 
inhibitor domain 1
 DTL 137.08 18.77 7.304 1q32 Denticleless homolog
 ASPM 106.59 14.65 7.275 1q31 Asp (abnormal spindle) homolog, 
microcephaly associated 
(Drosophila)
 RPP25 559.88 77.72 7.203 15q24.2 Ribonuclease P/MRP 25 kDa 
subunit
 POTED 159.99 22.95 6.970 21q11.2 POTE ankyrin domain family, 
member D
 CEP55 70.85 11.37 6.232 10q23.33 Centrosomal protein 55 kDa
 BIRC5 700.49 112.55 6.224 17q25 Baculoviral IAP repeat containing 5
 HBD 3095.95 508.95 6.083 11p15.5 Delta-hemoglobin
 RCC1 130.10 21.43 6.072 1p36.1 Regulator of chromosome conden-
sation 1
 ARC 87.31 14.66 5.954 8q24.3 Activity-regulated cytoskeleton-
associated prote
 UBE2C 413.10 70.52 5.858 20q13.12 Ubiquitin-conjugating enzyme E2C
 CASC5 77.08 14.23 5.417 15q14 Cancer susceptibility candidate 5
 HIST1H3B 567.97 112.18 5.063 6p22.1 Histone cluster 1, H3b
Downregulated genes in carcinoids with a poor prognosis
 OTP 21.67 18 320.20 0.001 5q13.3 Orthopedia homeobox
 PCK1 15.17 2357.44 0.006 6q25.1 Phosphoenolpyruvate carboxyki-
nase 1
 ASB4 21.82 2941.85 0.007 7q21–q22 Ankyrin repeat and SOCS box 
containing 4
 FOLR1 46.28 5097.19 0.009 11q13–q14.1 Folate receptor 1
 SLC45A3 22.94 2046.66 0.011 1q32.1 Solute carrier family 45, member 3
 FOLR3 2.28 151.88 0.015 11q13 Folate receptor 3 (gamma)
 SOD3 1042.44 60 621.59 0.017 4p15.3–p15.1 Superoxide dismutase 3, 
extracellular
 DLG2 21.36 1020.66 0.021 11q14.1 Discs, large homolog 2
 GALNT14 75.05 3175.05 0.024 2p23.1 UDP-N-acetyl-alpha-d-
galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 
14
 CDH3 15.30 613.45 0.025 7q22.3 Cadherin-related family member 3
 IL20RA 12.37 463.20 0.027 6q23.3 IL20RA interleukin 20 receptor, 
alpha
 SFTA3 10.04 319.08 0.031 14q13.3 Surfactant associated 3
 B3GAT1 33.05 1028.62 0.032 11q25 Beta-1,3-glucuronyltransferase 1 
(glucuronosyltransferase P; CD57)
 KIRREL3 19.74 597.56 0.033 11q24 Kin of IRRE like 3
 CD44 9.83 288.91 0.034 11p13 CD44 molecule (Indian blood 
group)
 KLHDC8A 34.82 1019.71 0.034 1q32.1 Kelch domain containing 8A
 LECT1 15.95 414.96 0.038 13q14.3 Leukocyte cell-derived chemotaxin
 ADAMTS18 11.87 271.31 0.044 16q23 ADAM metallopeptidase with 
thrombospondin type 1 motif, 18
 RGN 32.89 722.83 0.046 Xp11.3 Regulacin
 FXYD2 38.92 845.24 0.046 11q23 FXYD domain containing ion 
transport regulator 2
 LPL 217.26 4576.94 0.047 8p22 Lipoprotein lipase
 TESC 945.69 19 893.72 0.048 12q24.22 Tescalcin
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Of the 48 genes downregulated with a median fold change ≥5 in 
the poor prognosis group, 6 were located on chromosome 11q and 
4 were members of the gene family of metallothioneins, i.e. MT1F, 
MT1G, MT1M and MT1X (Table II). Also the tumor suppressor 
genes ADAMTS18, RELN and SOD3 were strongly downregulated 
in this group.
Validation of gene expression profiling results by qRT–PCR
To examine whether the results of the microarray study are reproduc-
ible, we performed qRT–PCR on the same 10 cases for a subset of 
up- and downregulated genes identified in the microarray. The down-
regulated genes CD44 (10), FOLR1, IL20RA, MT1F, OTP (10) and 
PCK1, as well as the upregulated BIRC5, BUB1, FANCA, KLK12 and 
RET (10) genes were selected from those listed in Table II based on 
their fold change in gene expression and/or their possible role(s) in dis-
ease progression. The microarray results could be reproduced for all 
genes tested, i.e. the expression trends were confirmed in the majority 
of the samples (Supplementary Table S3, available at Carcinogenesis 
Online). In addition, the prognostic value of the expression of the 11 
selected genes was tested using qRT–PCR on an additional group of 
55 carcinoid tumors. The qRT–PCR data were correlated with clini-
cal patient follow-up data, when available. Using the Kaplan–Meier 
method, all genes described above were significantly associated with 
prognosis as shown in Figure 1  and as described previously for CD44, 
OTP and RET (10). In multivariate analyses, comparing the individual 
genes with clinical parameters (age at diagnosis, diameter, histopa-
thology, sex), BIRC5 (P = 0.0066), BUB1 (P = 0.0023), CD44 (P = 
0.012), IL20RA (P = 0.036), KLK12 (P = 0.030) and OTP (P = 0.032) 
were independent predictors of patient outcome. These findings were 
also validated at the protein level by immunohistochemical staining of 
CD44 and OTP, which were shown to be powerful prognostic indica-
tors for lung carcinoids (10).
Thus, the microarray results were confirmed by qRT–PCR both 
through the prognostic value of a selection of 11 differentially 
expressed genes and by the similar ranking of their expression 
levels for the 10 samples (Supplementary Table S3, available at 
Carcinogenesis Online).
Identification of signaling pathways underlying carcinoid 
progression
Key pathways involved in carcinoid progression were queried by 
linking the list of 307 differentially expressed genes (Supplementary 
Table S1, available at Carcinogenesis Online) to the KEGG pathway 
database (http://www.genome.jp/kegg) using the online DAVID anno-
tation tool (http://david.abcc.ncifcrf.gov/). Cell cycle and DNA dam-
age detection and repair pathways were significantly altered (data not 
Gene abbreviationb Median (poor prognosis) Median (good prognosis) Median fold change Chromosomal locationc Gene name
 SLC1A2 15.33 264.78 0.058 11p13–p12 Solute carrier family 1
 ELMO1 65.12 1095.59 0.059 7p14.1 Engulfment and cell motility 1
 MT1F 652.32 10 455.69 0.062 16q13 Metallothionein 1F
 PGC 7.31 106.22 0.069 6p21.1 Progastricsin
 RELN 3.54 47.69 0.074 7q22 Reelin
 MT1M 27.31 291.10 0.094 16q13 Metallothionein 1M
 MRAS 273.50 2805.97 0.097 3q22.3 Muscle RAS oncogene homolog
 MCTP2 36.37 359.79 0.101 15q26.2 Multiple C2 domains, transmem-
brane 2
 C10orf114 66.79 657.29 0.102 10p12.31 Overlapping with MiRNA1915
 CA4 12.71 123.79 0.103 17q23 Carbonic anhydrase IV
 GHSR 48.72 451.47 0.108 3q26.31 Growth hormone secretagogue 
receptor
 EFCAB10 3.51 31.72 0.111 7q22.3 EFCAB10: EF-hand calcium-bind-
ing domain 10
 DNAJC22 204.18 1739.58 0.117 12q13.12 DnaJ (Hsp40) homolog, subfamily 
C, member 22 (wurst)
 PLAG1 125.83 1056.82 0.119 8q12 Pleiomorphic adenoma gene 1
 SCTR 7.22 59.12 0.122 2q14.1 Secretin receptor
 TSC22D1 51.99 400.74 0.130 13q14 TSC22 domain family, member 1
 MPPED2 12.60 94.69 0.133 11p13 Metallophosphoesterase domain 
containing 2
 LRRFIP1 62.69 459.87 0.136 2q37.3 Leucine rich repeat (in FLII) inter-
acting protein 1
 MT1G 1486.93 10 773.20 0.138 16q13 Metallothionein 1G
 STOX1 51.59 368.36 0.140 10q22.1 Storkhead box 1, DNA-binding 
domain
 VSTM2L 144.95 991.69 0.146 20q11.23 V-set and transmembrane domain 
containing 2 like
 LRRFIP1 112.75 628.40 0.179 2q37.3 Leucine rich repeat (in FLII) inter-
acting protein 1
 SERPINE2 87.04 470.24 0.185 2q33–q35 Serpin peptidase inhibitor, clade 
E (nexin, plasminogen activator 
inhibitor type 1), member 2
 FRMPD1 17.37 93.80 0.185 9p13.2 FERM and PDZ domain contain-
ing 1
 MT1X 157.63 844.65 0.187 16q13 Metallothionein 1X
 MAN2A1 93.32 468.95 0.199 5q21–q22 Mannosidase, alpha, class 2A, 
member 1
aThe genes displayed here were selected from the 307 differentially expressed genes displayed in Supplementary Table S1, available at Carcinogenesis Online. 
Selected genes are annotated, display a median fold change difference in expression levels ≥5 and have an expression level ≥200 for at least one of the samples. 
When multiple probes and/or amplicons showed a significantly different expression, only the probe displaying the largest median fold change difference is listed.
bGene abbreviations.
cSource of chromosomal locations shown in this table: UCSC genome browser (UCSC Genome Bioinformatics, version GRCh37/hg19, Santa Cruz, CA).
Table II. Continued
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shown). These pathways included well-known cancer-related genes, 
such as CDK1/2, cyclins and TP53, which were upregulated in car-
cinoids with a poor prognosis (Supplementary Table S1, available 
at Carcinogenesis Online). Strikingly, except for BUB1, none of the 
71 top candidates shown in Table II were annotated to these path-
ways. Therefore, we performed an extensive manual literature search 
in combination with the online BioGRID tool (http://thebiogrid.
org/) for protein interactions. As a result, a network of four inter-
connected pathways related to mitotic control mechanisms could be 
inferred from upregulated genes (Figure  2). This network included 
genes involved in (i) the mitotic spindle checkpoint (MSC); (ii) the 
CPC; (iii) mitotic kinase CDC2 activity and (iv) the BRCA-Fanconi 
Fig. 1. Survival analyses of pulmonary carcinoids based on qRT–PCR of genes differentially expressed between tumors with a favorable and a poor prognosis. 
Kaplan–Meier survival analyses of pulmonary carcinoid tumors depicting the difference in 15 year overall survival for high (solid lines) or low (dotted lines) 
mRNA levels of a selection of differentially expressed genes relative to the geometric mean of ACTB and CYPA, and the sample with the highest expression (see 
Supplementary Materials and methods, available at Carcinogenesis Online). Optimal cutoff values were determined based on area under the receiver operating 
characteristic curve analyses. These cutoff points were 0.0020 for BIRC5 (A), 0.0078 for BUB1 (B), 0.012 for FANCA (C), 0.00080 for FOLR1 (D), 0.15 for 
IL20RA (E), 0.0070 for KLK12 (F), 0.018 for MT1F (G) and 0.0011 for PCK1 (H).
Page 6 of 12
Gene expression profiling of pulmonary carcinoids
anemia (FA) pathway. The identified interactions between the indi-
vidually upregulated factors involved in these pathways are depicted 
in Figure  2 and justified in Supplementary Figure S2, available at 
Carcinogenesis Online.
Some of the genes from these pathways, i.e. BIRC5, BUB1 and 
FANCA, were validated by qRT–PCR as described above and found to 
be upregulated in poor prognostic cases (see Figure 1).
Upregulation of mitotic genes in relation to chromosomal instability
Alterations of the MSC and CPC proteins have been reported to pro-
voke chromosomal instability (CIN) (24,25). To identify chromosomal 
alterations in the 10 cases subjected to gene expression profiling, we 
performed high-resolution array CGH. The five carcinoid cases with 
a good prognosis generally exhibited low numbers of chromosomal 
alterations (≥10 Mb; mean 3, range 0–11; Supplementary Figure S1A, 
available at Carcinogenesis Online), whereas the five poor progno-
sis cases displayed a higher variability in the numbers of alterations 
(mean 12, range 0–27) (Table IC). Unexpectedly, one of the aggres-
sive tumors (case 2)  did not show major chromosomal alterations 
(Supplementary Figure S1B, available at Carcinogenesis Online), 
whereas two other poor prognosis cases (cases 1 and 4)  displayed 
CIN, defined as described previously (9) (Supplementary Figure 
S1C, available at Carcinogenesis Online). These two cases exhibited 
higher expression of a number of mitotic genes than the other sam-
ples (without CIN), most notably ASPM and UBE2C (Supplementary 
Table S1, available at Carcinogenesis Online). Together, these data 
suggest a possible relationship between the upregulation of mitotic 
genes and CIN.
Amplifications (high copy number gains) and homozygous dele-
tions of chromosomal regions were rare in the carcinoid cases. Five 
different amplifications and two homozygous deletions (present in at 
least two cases) could be identified (Table IC), including 8p11.2 that 
was homozygously deleted in four cases.
Upregulation of CPC components in relation to prognosis
As described above and shown in Figure  2, several of the upregu-
lated genes, including BIRC5 (survivin), could be linked to the CPC, 
with its major enzymatic component being ABk. This component 
was in itself not differentially expressed by the five cases with a poor 
outcome.
To further examine the role of the CPC in carcinoid progression, 
the messenger RNA (mRNA) expression levels of AURKB and BIRC5 
were analyzed in 65 carcinoid tumors and found to be strongly cor-
related with each other (P < 1e−36, Pearson’s correlation; Figure 3A 
and B) and with prognosis (see Figure 1A for BIRC5 and Figure 3C 
for AURKB). In general, low expression levels were evident for both 
genes in carcinoids, whereas considerably higher expression levels 
were only present in a few ACs (Figure 3A and B), as well as in the 
carcinoid cell lines H720 and H727 (Figure 3D and E).
Protein expression levels of ABk and survivin were assessed 
in 50 carcinoids by immunohistochemical staining (Figure 4A–C 
and Supplementary Table S4, available at Carcinogenesis Online) 
and again, a strong correlation between the expression of both 
proteins was seen (P = 7.2e−15, Pearson’s correlation). ABk as 
well as survivin could exhibit nuclear and/or cytoplasmic reac-
tivity. Nuclear ABk expression was present in ≤5% of nuclei of 
Fig. 2. Pathways related to lung carcinoid progression. Relationships between proteins encoded by upregulated genes in carcinoid tumors with an adverse disease 
outcome were compiled from data in the literature. Note that only relevant parts of the pathways are shown. The genes are taken from the lists in Table II (≥5-fold higher 
expressed in carcinoids with a poor prognosis; depicted as dark boxes) and Supplementary Table S1, available at Carcinogenesis Online (white circles). Genes in gray 
circles were not upregulated in our microarray but are related to multiple upregulated genes. B (for binding) indicates physical interactions between proteins. When 
these interactions lead to a phosphorylation event, this is indicated by P. TA indicates activation at the transcriptional (mRNA) level and A indicates posttranscriptional 
activation, whereas a bar-headed line indicates repression. UB indicates that the factor referred to is targeted to proteasomal degradation by the other factor, e.g. by 
ubiquitylation. The identified interactions between the depicted factors are summarized in the Supplementary Figure S2, available at Carcinogenesis Online.
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most carcinoid tumors (Figure  4A), with the exception of three 
cases (Figure  4B). Two of these three cases were included in 
the qRT–PCR and array CGH series and also exhibited higher 
mRNA levels, as well as CIN. The case with the highest mRNA 
expression, however, displayed strong cytoplasmic reactivity only 
(Figure 4C). Although the disease outcome for cases displaying 
ABk-positive cell frequencies >1% tended to be slightly worse 
(Figure 4D), the difference with cases without nuclear ABk reac-
tivity was not significant.
The number of positive nuclei for survivin was on average higher as 
compared with ABk (3.6 and 1.7%, respectively), as could be expected 
from the microarray data. Only few cases showed expression in >10% 
of nuclei (Supplementary Table S4, available at Carcinogenesis 
Online and Figure  4B). A  number of cases exhibited a prominent 
cytoplasmic staining reactivity for survivin (Supplementary Table S4, 
available at Carcinogenesis Online). Again, the case with the high-
est gene expression levels displayed strong cytoplasmic reactivity, but 
almost no nuclear expression (Figure 4D). Survivin protein expres-
sion in cases with >2.5% positive nuclei was also related to poor dis-
ease outcome (Figure 4D).
At the mRNA level, both AURKB (P = 0.00063, 95% confi-
dence interval = 0.0279–0.0843) and BIRC5 (P = 0.000049, 95% 
confidence interval = 0.0220–0.0505) were significantly higher 
expressed in neuroendocrine lung carcinomas as compared with the 
carcinoids (Figure 3D and E). Fifteen high-grade neuroendocrine 
carcinomas were analyzed for ABk and survivin protein expression 
using immunohistochemistry (Supplementary Table S4, available at 
Carcinogenesis Online). Although not all carcinomas showed stain-
ing for ABk, these tumors exhibited positivity in a much higher 
number of cases, and for the individual cases in a much higher fre-
quency of nuclei (mean 25%, range 0–59%; Figure 4E). The same 
holds true for survivin (mean 40%, range 22–74%; Figure 4E).
Downregulation of 11q-located genes
Three out of five samples with a poor prognosis displayed deletion 
of chromosome 11q, reported previously as an indicator of adverse 
disease outcome in carcinoids (9). Significantly more downregulated 
genes are located on this chromosome arm as compared with other 
chromosome arms (P = 0.00017; Supplementary Table S5, available 
at Carcinogenesis Online). With the exception of FOLR1, the genes 
that were downregulated >5 times (Table II) displayed a tendency 
toward lower expression in the three cases combining a poor progno-
sis with a deletion of 11q, as compared with the two poor prognosis 
cases not containing this deletion (Supplementary Table S1, available 
at Carcinogenesis Online). This could indicate that the loss of one 11q 
chromosome arm is (partly) responsible for the further decrease in 
gene expression, although this needs to be confirmed on larger tumor 
series.
Fig. 3. Gene expression levels of AURKB and BIRC5 in pulmonary NENs. (A and B) qRT–PCR results for AURKB and BIRC5 in typical carcinoids (TC) 
and ACs. (C) Kaplan–Meier survival analysis plot depicting the differences in 15 year overall survival for high (solid line) or low (dotted line) AURKB gene 
expression levels within the group of pulmonary carcinoid tumors. Cutoff level based on area under the receiver operating characteristic curve: 0.0051. (D and E) 
qRT–PCR results for TCs, ACs, large cell neuroendocrine carcinomas, SCLC, neuroendocrine cell lines (NECL) and normal tissue (NT) for AURKB and BIRC5. 
mRNA expression levels are relative to the geometric mean of ACTB and CYPA and the sample with the highest expression (see Supplementary Materials and 
methods, available at Carcinogenesis Online). The mean values are indicated by the horizontal bars.
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Discussion
This is the first gene expression profiling report focusing on the pro-
gression of pulmonary carcinoid tumors. The prognostic value of a 
number of candidate genes could be validated, whereas specific sign-
aling routes could be associated with the more aggressive behavior of 
carcinoids. In cases with adverse disease outcome, upregulated genes 
could be assigned to mitotic control pathways. In addition, multiple 
tumor suppressor genes and genes located at 11q were downregulated.
Downregulated genes located at 11q
As compared with other genomic regions, significantly more down-
regulated genes were located at chromosome 11q. In addition to MEN1 
mutations involved in the carcinogenesis of a subset of sporadic lung 
carcinoids (1,26), the presence of an additional tumor suppressor 
gene at 11q13 has since long been hypothesized because frequencies 
of loss of heterozygosity at 11q13 are higher than MEN1 mutation 
frequencies (26). Using qRT–PCR we observed earlier that MEN1 is 
indeed downregulated in carcinoids with a poor prognosis (27). Of the 
genes located at this chromosomal region, FOLR1 and FOLR3 were 
>5 times downregulated in the aggressive carcinoids. FOLR1 encodes 
the folate receptor α and is expressed in various epithelial tumors, 
whereas both FOLR1 and FOLR3 are highly expressed in ovarian 
carcinomas (28). Also in lung adenocarcinomas, higher expression of 
FOLR1 is associated with a favorable disease outcome (29).
Based on our previous study (9), candidate tumor suppressor genes 
at the telomeric part of chromosome 11q were also expected. A number 
of genes at this locus were >5 times downregulated, including discs 
large homolog 2 (DLG2) at 11q14.1. This gene encodes a membrane-
associated guanylate kinase involved in establishing and maintaining 
cell polarity in epithelial cells and neurons. Both FXYD domain con-
taining ion transport regulator 2 (FXYD2), the gamma-subunit of the 
NaK-ATPase, at 11q23, and Kin of IRRE like 3 (KIRREL3, also known 
as NEPH2) at 11q24 are expressed in dorsal root ganglions (30,31). 
The latter is a transmembrane protein involved in neuronal migration 
in the pontine nucleus and may play a role in axonal path finding and 
synapse formation of dorsal root ganglion neurons on appropriate tar-
gets (31,32). Beta-1,3-glucuronyltransferase 1 (B3GAT1, also known 
as CD57 and Leu7) is located at 11q25. Although CD57 positivity is 
mainly present on natural killer cells, Bunn et al. (33) demonstrated in 
an early study that the majority of SCLCs, as well as six out of six carci-
noids (without clinical information) tested were positive for this factor.
In addition to 11q deletion, some novel amplifications and homozy-
gous deletions could be identified in this study. For example, ADAM3A 
and ADAM5P (8p11.22) were homozygously deleted in four cases. This 
region was not identified in our previous report (9) due to higher resolu-
tion of the array CGH in the underlying study. ADAM3A was previously 
reported to be prone to homozygous loss in gliomas (34). Case 1 had an 
amplification of MYC at 8q24.21, as shown previously (9).
Pathways related to progression of pulmonary carcinoids
A network comprising of mitotic genes and BRCA-related genes 
was found to be upregulated in carcinoid tumors with a poor dis-
ease outcome (Figure  2). We studied a number of factors involved 
in this network in more detail by qRT–PCR and immunohistochem-
istry. The four identified pathways, i.e. the CPC, the MSC, CDK2 
and BRCA-FA pathway, have been thoroughly reviewed elsewhere 
(24,25,35–39), and the relationships between the factors upregu-
lated in the microarray experiments and involved in these signaling 
routes have been described in Supplementary Figure S2, available at 
Carcinogenesis Online.
In short, the CPC consists of ABk and three non-enzymatic subu-
nits, i.e. borealin, survivin and INCENP (36). These latter three fac-
tors control the activity, stability and targeting of ABk. The CPC has 
many functions during mitosis. Although initially located at chromo-
some arms, the complex is transferred during (pro)metaphase to the 
inner centromeres. Its most important function is probably the regu-
lation of kinetochore–microtubule attachments, where it can sense 
a lack of tension caused by inappropriate microtubule attachments, 
leading to mitotic arrest. However, the CPC is also indispensable for 
other stages of the cell cycle, e.g. mitotic spindle formation and com-
pletion of cytokinesis (36).
The MSC functions to enable proper chromosome separation dur-
ing mitosis by controlling the attachment of the kinetochores of the 
individual chromosomes to the mitotic spindle (24,35). The core 
mitotic checkpoint complex consists of BUB3, BUBR1, CDC20 and 
MAD2 and inhibits the anaphase-promoting complex/cyclosome, pre-
venting the start of the anaphase until all chromosomes are properly 
segregated (35). Although none of the core members of the mitotic 
checkpoint complex were upregulated in this microarray experi-
ment, several associated factors, such as CASC5 and BUB1, did show 
increased mRNA levels.
Fig. 4. ABk and survivin protein expression in pulmonary NENs and their 
relation to patient outcome. (A–C) Immunohistochemistry results of carcinoid 
tumors. (A) AC with a favorable prognosis (case 8), exhibiting nuclear 
reactivity in a small number of cells for both proteins. In addition, this case 
exhibits cytoplasmic reactivity for survivin. (B) Metastatic AC showing 
nuclear reactivity in a considerable fraction of cells for both proteins, with 
a higher frequency for survivin than for ABk. (C) AC with the highest gene 
expression for both AURKB and BIRC5 (see Figure 3A and B). This case has 
almost no positive nuclei but exhibits a strong cytoplasmic expression for both 
proteins. (D) Kaplan–Meier survival analyses of pulmonary carcinoid tumors 
depicting the difference in 15 year overall survival for high (solid lines) or low 
(dotted lines) protein expression levels of ABk and survivin. The cutoff value 
for ABk was arbitrarily set at 1% positive nuclei, whereas the cutoff value for 
survivin protein expression was determined at 2.5% based on area under the 
receiver operating characteristic curve analyses. (E) Immunohistochemistry 
result in a high-grade neuroendocrine carcinoma showing strong nuclear 
reactivity for both proteins. All original magnifications were ×200.
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In the BRCA-FA pathway, BRCA1, BRCA2 and RAD51 cooperate 
with the FA proteins in response to DNA damage to preserve chro-
mosomal stability (38). FANCA is a member of the core complex of 
FA proteins. This complex monoubiquitylates FANCD2 and FANCI, 
which migrate subsequently to foci also containing BRCA1, BRCA2 
and RAD51 in the nuclei of cells that have accumulated DNA damage 
(37,38).
Finally, several factors related to the main mitotic kinase CDC2/
CDK1 were upregulated, albeit <5 times. CDK1 is the main mitotic 
kinase and is activated by A-type cyclins at the end of interphase 
(39). It functions as a master regulator of mitosis and among its phos-
phorylation targets are >70 different substrates. After the MSC has 
ensured that all chromosomes are correctly attached to the mitotic 
spindle, CDK1 is inactivated through degradation of cyclin B.
It can be envisaged that slight alterations in the four interconnected 
pathways may have large effects on cell division and may therefore be 
involved in the progression of carcinoids. Several genes upregulated 
≥5 times in the identified network (Figure  2) have been described 
in the context of cancer. The CASC5 gene is upregulated in several 
types of cancer, including lung cancer, where it is associated with 
poor differentiation and smoking (40). BUB1 overexpression, found 
to be related to an adverse disease outcome, promotes hyperactivity 
of ABk and induces tumor formation in transgenic mice (41), whereas 
BUB1 mutations have been identified in colorectal cancer cell lines 
(42). Overexpression of UBE2C, shown in several types of cancer, 
is known to cause chromosome lagging, aneuploidy and tumor for-
mation in mice (43). Increased mRNA levels of ASPM have been 
reported in glioblastomas, and its inhibition was shown to repress 
tumor cell proliferation (44). SMOC-2 may be an angiogenic fac-
tor and was shown to upregulate among others histone H3, AURKB 
and CDC2 transcription when transduced into human umbilical vein 
endothelial cells (45).
In pulmonary carcinoids, increased mRNA levels of AURKB and 
BIRC5 were related to low survival rates. With respect to protein lev-
els, a significant relation with patient outcome was found for nuclear 
expression of survivin. For ABk, nuclear staining in carcinoid tumors 
was generally low, whereas most neuroendocrine carcinomas dis-
played stronger immunoreactivity. Survivin is overexpressed in many 
cancer types, including lung tumors (46). Although the expression of 
survivin has been extensively studied in non-SCLC (NSCLC) (47), 
reports on its expression in neuroendocrine lung tumors are consist-
ently lacking and also, to our knowledge, data on the expression 
of survivin in pulmonary carcinoids and large cell neuroendocrine 
carcinoma have not been previously published. Halasova et al. (48) 
recently reported lower frequencies and staining intensities in SCLCs 
as compared with other types of lung cancer, whereas Belyanskaya 
et al. (49) reported higher gene expression levels in SCLC cell lines 
as compared with NSCLC cell lines. Overexpression of ABk has been 
reported in NSCLC (50,51), but data on its expression have not been 
reported in (primary) lung NENs.
Next to genes located at chromosome 11q or involved in the four 
pathways, also a few other genes were validated as possible prognos-
tic indicators for pulmonary carcinoids. Of these, CD44, OTP and 
RET were discussed previously (10). Although RET was the strong-
est upregulated gene in the underlying study, it could not be directly 
related to other differentially expressed genes, although some of them 
may be among its downstream targets. KLK12 is a secreted serine pro-
tease (52), found to be upregulated in prostate cancer (53) and recently 
reported as a prognostic indicator for gastric cancer (54). Among its 
targets are matricellular proteins of the CCN (CYR61-CTGF-NOV) 
family (52). IL20-RA is one of the two subunits comprising together 
the IL20-receptor (55). These receptor subunits are upregulated in 
psoriatic skin, but individual functions for IL20-RA have not been 
described. MT1F is a member of the gene family of metallothioneins, 
from which also MT1G, MT1M and MT1X were significantly lower 
expressed in the messenger RNA microarray. Both tumor suppressive 
and oncogenic functions have been assigned to members of the MT1 
family of proteins (56), including MT1F (57,58). PCK1 has been 
described to be downregulated in colon cancer (59).
Relation of mitotic pathway alterations to CIN and Ki-67 
proliferation index
Alterations of both the MSC and CPC proteins have been reported 
to cause CIN (24,25) and both up- and downregulation of CPC 
members, including ABk, may cause this effect (60). Two of the 
five poor prognosis samples displayed extensive CIN and in these 
cases a stronger upregulation of a number of genes involved in the 
described pathways, particularly ASPM and UBE2C, was evident. 
These cases had in addition considerable mRNA expression levels 
of the MSC component BUB1 and the CPC components AURKB 
and BIRC5, which is in agreement with studies in NSCLC, where 
higher gene expression of AURKB has been demonstrated in tumors 
with genomic instability (50). Also SCLCs and large cell neuroen-
docrine carcinomas, tumors known to frequently exhibit CIN (1), 
demonstrated high gene expression levels of AURKB and BIRC5. In 
gene expression profiling studies conducted on SCLCs, the MSC 
components BUB1B and MAD2L1 were reported to be upregulated 
(61,62).
The same carcinoid cases that displayed CIN had an increased 
Ki-67 index. These cases were consensus classified as ACs by two 
experienced pathologists and were diploid in nature (9). However, 
they may represent borderline cases between ACs and high-grade 
lung NENs. This view is supported by the fact that one of these 
cases showed MYC amplification (9) and TP53 mutation, which are 
usually hallmarks of high-grade lung NENs (1,9). Carcinoid tumors 
exhibit usually <20% Ki-67-positive cells, but for ACs higher fre-
quencies have also been reported (12). Ki-67 is currently not a dis-
criminative criterion between carcinoids and high-grade pulmonary 
neuroendocrine carcinomas (2). Furthermore, CIN is not necessarily 
associated with a poor prognosis, as we have demonstrated previ-
ously (9).
Conclusion and future prospects
This study provides the first unmasking of possible genes involved 
in the malignant progression of lung carcinoids. We report sev-
eral genes that may serve as novel prognostic markers, including 
downregulated candidates on chromosome 11q, a locus earlier 
described to be frequently lost in aggressive cases (9). BIRC5, 
BUB1, CD44, IL20RA, KLK12 and OTP are found to be inde-
pendent predictors of patient outcome. Moreover, pathway analy-
sis showed the involvement of signaling routes related to mitotic 
control mechanisms in carcinoid progression, different from those 
mostly observed in carcinomas (63). These include the CPC and 
the MSC. Their upregulation is suggested to be related to CIN and 
enhanced proliferation.
Taking together this data, it is tempting to speculate about the driv-
ing factor(s) of carcinoid progression. Strong candidates include the 
tyrosine kinase receptor RET, which stimulates many downstream 
pathways and is most strongly upregulated in the microarray experi-
ment (10), as well as SMOC2, which upregulates AURKB. Further 
studies should focus on the identification of genes driving oncogen-
esis of pulmonary carcinoids and separate these from the passenger 
genes that have merely secondary effects on tumorigenesis.
Increased levels of ABk and survivin, both central in the CPC, were 
associated with poor disease outcome in the group of carcinoids. There 
are several lines of evidence that ABk and survivin may be therapeutic 
targets, also for neuroendocrine lung tumors. SCLC cell lines, par-
ticularly those with upregulation of one of the three MYC genes, are 
sensitive to the Aurora kinase inhibitor PF-03814735 (64). Recently, 
Sos et al. (65) have demonstrated that MYC-amplified SCLC cell lines 
are also sensitive to other Aurora kinase inhibitors and that the activity 
of these inhibitors is mainly dependent on ABk. Interestingly, one of 
the carcinoids with high ABk expression displays MYC amplification 
(9). Because survivin is not expressed by most normal adult tissues, it 
is also an attractive target for therapeutic intervention (46). Survivin 
inhibitors are currently under evaluation in clinical trials for several 
types of cancer (66), in which lung NENs, more in particular the high-
grade carcinomas, could be included.
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Supplementary Materials and methods, Tables S1–S5 and Figures S1 
and S2 can be found at http://carcin.oxfordjournals.org/
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